Atossa (NASDAQ: ATOS) director awarded 10,000 RSUs in stock grant

Rhea-AI Filing Summary

Remmel H. Lawrence reported acquisition or exercise transactions in this Form 4 filing.

ATOSSA THERAPEUTICS, INC. director Remmel H. Lawrence reported a compensation-related stock grant. He received 10,000 restricted stock units, each representing one share of common stock at no cash cost. These RSUs vest on the first anniversary of May 12, 2026. After this award, Lawrence directly holds 10,683 shares of common stock, reflecting a relatively small, routine equity grant rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Remmel H. Lawrence

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10,000	$0.00	--

Holdings After Transaction: Common Stock — 10,683 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 10,000 RSUs Shares held after grant: 10,683 shares Grant price per share: $0.0000 per share +1 more

4 metrics

RSU grant size 10,000 RSUs Grant of restricted stock units to director on May 12, 2026

Shares held after grant 10,683 shares Total direct common stock holdings following RSU award

Grant price per share $0.0000 per share Reported transaction price for RSU grant

RSU vesting timing First anniversary of May 12, 2026 Vesting schedule for granted restricted stock units

Key Terms

restricted stock units ("RSUs"), Grant, award, or other acquisition, contingent right

3 terms

restricted stock units ("RSUs") financial

"Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Remmel H. Lawrence

(Last) (First) (Middle)

C/O ATOSSA THERAPEUTICS, INC.

1448 NW MARKET STREET SUITE 500

(Street)

SEATTLE WASHINGTON 98107

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ATOSSA THERAPEUTICS, INC. [ ATOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/12/2026		A		10,000(1)	A	$0	10,683	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026.

	H. Lawrence Remmel	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ATOS director Remmel H. Lawrence report on this Form 4?

Remmel H. Lawrence reported receiving 10,000 restricted stock units as a grant. Each RSU represents a contingent right to one share of Atossa Therapeutics common stock, awarded at no cash cost as part of his director compensation.

How many ATOS shares does Remmel H. Lawrence hold after this RSU grant?

After the reported grant, Remmel H. Lawrence directly holds 10,683 shares of Atossa Therapeutics common stock. This total includes the effect of the 10,000 restricted stock units disclosed in the filing as a grant, award, or other acquisition.

When do Remmel H. Lawrence’s ATOS restricted stock units vest?

The restricted stock units granted to Remmel H. Lawrence vest on the first anniversary of May 12, 2026. Vesting means he must remain eligible through that date before each RSU converts into one share of common stock.

Was Remmel H. Lawrence’s ATOS transaction an open-market purchase or a grant?

The transaction was a grant of restricted stock units, not an open-market purchase. It is classified as a “grant, award, or other acquisition,” reflecting equity-based compensation rather than a discretionary stock buy on the public market.

What does each ATOS restricted stock unit (RSU) granted to Remmel H. Lawrence represent?

Each restricted stock unit represents a contingent right to receive one share of Atossa Therapeutics common stock. The units convert into shares only after the vesting condition is satisfied on the first anniversary of May 12, 2026.